World Equity Group, Inc. Alnylam Pharmaceuticals, Inc. Transaction History

World Equity Group, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 18, 2024	BUY	$146.51 - $198.2 $462,239 - $625,321	3,155 New	3,155 $472 Million
Q4 2023 Jul 22, 2024	SELL	$151.41 - $196.57 $57,535 - $74,696	-380 Reduced 11.2%	3,013 $577 Million
Q3 2023 Jul 22, 2024	BUY	$170.77 - $211.65 $40,643 - $50,372	238 Added 7.54%	3,393 $601 Million
Q2 2023 Aug 26, 2024	SELL	$185.01 - $212.05 $5.62 Million - $6.44 Million	-30,380 Reduced 90.85%	3,060 $581 Million
Q1 2023 Aug 26, 2024	BUY	$182.66 - $235.53 $5.53 Million - $7.13 Million	30,285 Added 959.9%	33,440 $863 Million
Q4 2022 Sep 06, 2024	SELL	$185.53 - $241.31 $5,751 - $7,480	-31 Reduced 1.03%	2,974 $707 Million
Q3 2022 Sep 06, 2024	SELL	$138.54 - $232.0 $20,781 - $34,800	-150 Reduced 4.75%	3,005 $601 Million
Q2 2022 Sep 06, 2024	SELL	$120.42 - $169.29 $5,659 - $7,956	-47 Reduced 1.52%	3,049 $445 Million
Q1 2022 Sep 06, 2024	SELL	$127.18 - $173.91 $7,503 - $10,260	-59 Reduced 1.87%	3,096 $506 Million

639

107M

2.33M

2.15M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of World Equity Group, Inc., based on Form 13F filings with the SEC.

Stay updated on World Equity Group, Inc. with notifications on news.